Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Solta Medical, Inc.
Type
Public company
Traded as
  • NYSE: VRX
  • TSX: VRX
  • S&P/TSX 60 component
Industry Pharmaceutical industry
Founded 1960 (1960)
Headquarters Laval, Quebec, Canada
Key people
  • J. Michael Pearson (Chairman & CEO)
  • Howard B. Schiller (CFO)
Products
  • Cesamet (nabilone)
  • Efudex
  • Mestinon
  • Diastat
  • Ribavirin (licensed to Schering Plough)
  • CeraVe
Revenue Increase US$2.73 billion (Q2 2015)
Operating income
Decrease US$341.5 million (Q2 2015)
Net income
Decrease US$-56.1 million (Q2 2015)
Subsidiaries
  • Bausch & Lomb
  • Salix Pharmaceuticals
  • Medicis Pharmaceutical
  • Solta Medical
  • Dendreon
  • OraPharma
  • Obagi
Website valeant.com

Valeant Pharmaceuticals International, Inc. is a publicly traded pharmaceutical company based in Montreal, Canada. The company focuses on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s.

Aton Pharmaceuticals
(Acq 2010)

Vital Science Corp
(Acq 2010)

Laboratoire Dr. Renaud
(Acq 2009)

Tecnofarma
(Acq 2009)

Dow Pharmaceutical Sciences Inc
(Acq 2009)

DermaTech
(Acq 2009)

Coria Laboratories Ltd

Xcel Pharmaceuticals
(Acq 2005)

Biovail

Prestwick Pharmaceuticals
(Acq 2008)

Pharma PASS
(Acq 2002)

Fuisz Technologies Ltd
(Acq 1999)

Medicis Pharmaceutical
(Acq 2012)

Ucyclyd Pharma
(Acq 1999)

GenDerm Corporation
(Acq 1997)

PharmaSwiss S.A.
(Acq 2011)

Sanitas Group
(Acq 2011)

iNova
(Acq 2011)

Probiotica Laboratorios Ltda
(Acq 2012)

Eyetech Inc
(Acq 2012)

Pedinol
(Acq 2012)

OraPharma
(Acq 2012)

Natur Produkt
(Acq 2013)

Obagi Medical Products Inc
(Acq 2013)

Bausch & Lomb
(Acq 2013)

Solta Medical Inc
(Acq 2014)

PreCision Dermatology
(Acq 2014)

Salix Pharmaceuticals
(Acq 2015)

Dermik
(Acq 2011)

Dendreon
(Acq 2015)

Amoun Pharmaceutical
(Acq 2015)

Sprout Pharmaceuticals Inc
(Acq 2015)

Synergetics USA
(Acq 2015)

Investment goal date:
Dividends reinvested
Solta Medical, Inc. SLTM report
Period
Date
Adjusted Actuals EPS
GAAP EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
FANNING STEPHEN J
0.9700% (779212)
SLTM /
Carnell Clint
0.2000% (162710)
BSDM / SLTM /
Knowlton Edward W
1.1300% (912975)
SLTM /
Brodie William
0.2000% (159749)
SLTM /
Foss Kristine A
0.1300% (108711)
SLTM /
% ()